Melanoma News & Analysis
2 articles
Market Mood
Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.
Read More: Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) cancer vaccine trial shows positive early results
In its first late-stage trial, a personalized cancer vaccine from Moderna (MRNA) and Merck showed positive results. The trial involved over 1,100 patients with higher-risk melanoma and met key goals, significantly extending time until cancer recurrence compared to Keytruda alone. Following the announcement, Merck's stock rose over 8% and Moderna's shares soared about 100%. The trial's success suggests that this combination could be a significant new treatment option for melanoma, impacting future drug development and potential market dynamics for these companies.
Read More: Moderna (MRNA) cancer vaccine trial shows positive early results